Combined Transplantation of Human MSCs and ECFCs Improves Cardiac Function and Decrease Cardiomyocyte Apoptosis After...

Area of Science:

• Regenerative Medicine
• Cardiovascular Research
• Cell Therapy

Background:

• Ischemic heart disease, particularly acute myocardial infarction (AMI), remains a leading cause of death globally.
• Millions of AMI patients develop heart failure annually despite advances in treatment.
• Early ischemic damage and impaired angiogenesis contribute to adverse cardiac remodeling post-AMI.

Purpose of the Study:

• To evaluate the efficacy of combined human mesenchymal stromal cells (MSCs) and endothelial colony-forming cells (ECFCs) therapy.
• To assess the potential of MSCs to reduce early ischemic damage and ECFCs to enhance angiogenesis.
• To investigate the therapeutic effects in a preclinical model of acute myocardial infarction (AMI).

Main Methods:

• NOD/SCID mice underwent induced AMI and received transplantation of MSCs and/or ECFCs or vehicle control.
• Cardiomyocyte apoptosis was assessed one day post-AMI.
• Cardiac function, infarct size, and fibrosis were evaluated four weeks post-AMI.

Main Results:

• MSC and ECFC combination therapy significantly reduced cardiomyocyte apoptosis compared to controls.
• Treatment led to a significant decrease in infarct size and cardiac fibrosis.
• Improved functional cardiac recovery was observed in treated animals four weeks after AMI.

Conclusions:

• Combined ECFC and MSC therapy effectively reduces cardiomyocyte apoptosis, scar size, and adverse cardiac remodeling in an AMI model.
• This combination cell therapy approach shows promise for future human studies in acute ischemic cardiac injury.
• The findings support the use of combined cell therapy for mitigating early ischemic damage and promoting cardiac repair.